Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
about
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeRisk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten yearsNew and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.New options in anticoagulation for the prevention of venous thromboembolism and stroke.New anticoagulants for the prevention of venous thromboembolism.Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery.Inhibitors of propagation of coagulation: factors V and X.Novel drugs for oral anticoagulation pharmacotherapy.Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects.Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerationsThe pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
P2860
Q24623137-44CE448F-6A32-4A6C-9380-BB3C1666B878Q28082967-2EEF1DA1-1122-44A5-BA6E-341BEF2F72BAQ33397359-23B4E6EB-C319-4F54-BB49-1CAFDC21242FQ34906214-38720DDE-72A7-4556-8EE2-9BD60D39DE3BQ37763535-4423CC07-F337-4B8F-83B9-DC3F11343A1BQ37847150-8BF05C6B-1BA6-431A-BBBC-DB0A25173932Q37872338-7FB508CF-8AA6-45E6-B7AF-6E42A9D77DFDQ37998113-AAC5139F-8427-4A38-81BC-B95AD5F5833BQ38012153-99555A07-2C69-4552-931B-0FC0A8B8F77BQ39816052-6A392DD5-B661-4614-ACE6-D775354B7D8AQ40539614-245DF87D-99C2-46EA-8DDB-117BF20D9CBDQ41816924-73425165-09A7-41B7-BC19-0DDCBE77DA3EQ46153031-5E759C24-B5EC-4B5B-951A-EF269C7D09F3Q51216572-EC7DE102-50D3-40CC-A028-74F67CE0AD87
P2860
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@en
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@nl
type
label
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@en
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@nl
prefLabel
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@en
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@nl
P2093
P1476
Prevention of venous thromboem ...... A dose finding study (ONYX-2).
@en
P2093
A G G Turpie
B I Eriksson
G Wetherill
J W Wilpshaar
M R Lassen
ONYX-2 STUDY GROUP
P304
P356
10.1111/J.1538-7836.2010.03748.X
P577
2010-01-17T00:00:00Z